leish-f3
Vaccineexperimental
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2012 (NCT01484548)
Timeline
2010s
- Jan 1, 2012
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- LeishmaniaImmunity, active
Leishmania immunity, active
Chemistry & pharmacology
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4650404 ↗
Also known as
- leish-f3
- leish-f3 + gla-se
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02071758 | Phase 1 | Apr 1, 2014 | Bill and Melinda Gates Foundation, Immune Design, Infectious Disease Research Institute |
| NCT01751048 | Phase 1 | Mar 1, 2013 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT01484548 | Phase 1 | Jan 1, 2012 | Immune Design, Infectious Disease Research Institute |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Immune Design | For profit | 2 | 0 | 1 | 2012 |
| Infectious Disease Research Institute | Academic/Hospital | 2 | 2 | 1 | 2012 |
| Bill and Melinda Gates Foundation | Academic/Hospital | 1 | 0 | 1 | 2014 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 1 | 1 | 1 | 2013 |
4 organizations
Page 1 / 1